These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35533814)

  • 1. Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.
    Nozawa K; Takatsuka D; Endo Y; Horisawa N; Ozaki Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Crit Rev Oncol Hematol; 2022 Jun; 174():103703. PubMed ID: 35533814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
    Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
    BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
    J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
    Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
    JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
    Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials.
    Zhang H; Huang Z; Zou X; Liu T
    Oncotarget; 2016 Dec; 7(50):82473-82481. PubMed ID: 27756883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
    Chen J; Lu Y; Zheng Y
    Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Ma Z; Sun X; Feng X; An Z
    Breast; 2022 Apr; 62():162-169. PubMed ID: 35219113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
    Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
    JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ahmadizar F; Onland-Moret NC; de Boer A; Liu G; Maitland-van der Zee AH
    PLoS One; 2015; 10(9):e0136324. PubMed ID: 26331473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.
    An MM; Zou Z; Shen H; Liu P; Chen ML; Cao YB; Jiang YY
    Eur J Clin Pharmacol; 2010 Aug; 66(8):813-21. PubMed ID: 20401474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.